Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole with Lapatinib + Letrozole in Recurrent or Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy Revised Protocol 02, incorporating Protocol Amendments 02 and 04 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0 dated 20-Nov-09)

Next Previous
Trial Profile

An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole with Lapatinib + Letrozole in Recurrent or Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy Revised Protocol 02, incorporating Protocol Amendments 02 and 04 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0 dated 20-Nov-09)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BMS 690514 (Primary) ; Lapatinib; Letrozole
  • Indications Advanced breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use

Most Recent Events

  • 23 May 2013 Planned number of patients changed from 140 to 175 as reported by European Clinical Trials Database.
  • 07 Apr 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
  • 07 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top